

China explores new mode of pharmaceutical R&D

03 May 2021 | News | By Manbeena Chawla

Link Health and George Clinical to establish an independent joint venture clinical development company



Guangzhou Link Health Pharma Co., Ltd. (Link Health), based in China, and Australian firm George Clinical Pty Ltd (George Clinical) have signed a term sheet to enter into a strategic agreement to establish an independent joint venture clinical development company called Link-George Clinical Research Co., Ltd (Link-George).

Link-George will deliver clinical trials for Link Health and related companies that it has entered into licensing deals with. The plan is for Link-George to launch six clinical trials in 2021 and this is expected to grow as Link Health's in-licensed portfolio expands.

Link-George will be majority owned by Link Health and operationally led by George Clinical with a board that comprises representatives from both Link Health and George Clinical.

George Clinical is a leading Asia Pacific contract research organization with more than 20 years of experience and a global reach across 38 countries. Collaborating with clients in the areas of biopharmaceuticals, medical devices and diagnostics, it provides a full range of clinical trial services related to all trial phases, registration and post-marketing trials.